Medical news that moves from positive to negative may lead consumers to overreact

istockphoto - Early reports are often upbeat, but they can turn negative after experiences with new drugs, therapies reveal problems.

Health reporting often follows an all-too-familiar pattern: New drugs or therapies are introduced with glowing accounts, followed a few years later by headlines warning about their dangers. Some people react to that uncertainty by dismissing all health and medical news, while others overreact by adopting — or abandoning — strategies too soon.

Part of the confusion stems from the normal unfolding of scientific knowledge, which is constantly evolving as new evidence adds to the existing body of research. But fault also lies in the way that medical research is published and pushed through the media, creating a broken system that has tremendous potential to harm consumers, says Gary Schwitzer, publisher of HealthNewsReview.org, a watchdog Web site that tracks the quality of health reports.

More science news

Why most humans are not vegetarians

Why most humans are not vegetarians

Eating meat and cooking food enabled the brains of prehumans to grow dramatically over time.

Sea snails weaken in Antarctic waters

Sea snails weaken in Antarctic waters

Carbon dioxide makes the waters of the Southern Ocean increasingly acidic.

Sensors alert fish as threats approach

Sensors alert fish as threats approach

Neuromasts help them sense when a predator is near, even if the water is muddy or the fish can’t see.

The following checklist will help you sift through the rubble of medical news you find online, on TV and in print.

Check the background. Was the study published? If you don’t see the name of a peer-
reviewed medical journal and a publication date in an article, either pass or take the findings as preliminary. The journalist might be covering early research that is often presented at medical conferences. Such presentations aren’t peer-reviewed, and the findings might change if or when they are published.

Who paid for it? Health-care research is rife with potential conflicts of interest. Pharmaceutical firms have provided almost 60 percent of all biomedical research funding in the United States, raising questions about the integrity of some drug studies. In January 2007, the online journal PLoS published an analysis of nutrition studies involving soft drinks, juice or milk; it found that more than half had industry funding. More important, the studies’ conclusions directly correlated with who funded them.

What’s the context? A single study seldom constitutes strong evidence of anything and is even more rarely considered a clinical game changer. Instead, new conclusions should be presented in the context of what is already out there. Does the finding support existing evidence? Suggest a new benefit that warrants investigation? Raise safety concerns that earlier studies didn’t? Knowing where the new research fits in the body of existing data can help you decide what to make of it.

Examine the methodology. Was it a controlled clinical trial or an observational study? The gold standard in medical research is the double-blind, randomized, controlled clinical trial, in which subjects are randomly assigned to a control (placebo) or experimental (active drug, substance or therapy) group. Neither the subjects nor the researchers know who is in which group until the study ends. In general, the more people who are in a clinical trial — ideally, hundreds or even thousands — the more weight you can put on the findings.

Observational studies, in contrast, compare large populations of people and look for connections between their habits and behaviors and various health outcomes. Those studies can suggest a link — say, between eating blueberries and strong brain function, or laughing a lot and lower blood pressure — but can’t prove a causal effect.

Loading...

Comments

Add your comment
 
Read what others are saying About Badges

    Pastor’s tornado tweets stir up a theological debate